Amgen awarded Accure a Golden Ticket to accelerate biomarker discovery and testing (2022).

Accure was selected as a Biogen Golden Ticket Award Winner (2022).

Accure's CEO Jessica Sang was featured as a Next Generation Leader in the LabCentral Impact Report (2022).

Novel Saliva Assay by Accure Health Tracks COVID-19 Vaccine Response in Proof-of-Concept Study (2021).

New publication in Nature Biomedical Engineering demonstrated the potential of Accure's high-throughput EV analysis for detecting colorectal cancer with >96% accuracy (2021).

The Blavatnik Family Foundation highlights Accure's efforts in addressing COVID-19 (2020).

Accure was named a finalist in the President’s Innovation Challenge (2020).

Accure's story was featured in the Harvard Innovation Lab Highlight (2019).

Accure's CEO Jessica Sang was invited to join the Forbes Business Council (2019).

Accure joined the highly selective BrainMind ecosystem founded by Michael McCullough and Reid Hoffman (2019).

Accure team member summited Mt. Everest and carried Accure's logo flag to the summit (2018).

Accure's iEAT keychain device was highlighted in the MGH News, NIH News, TechCrunch and CBS News (2017).

Accure received a competitive SBIR grant from the National Cancer Institute to advance its digital diagnostics (2017).

Accure was selected to join the prestigious Pagliuca Harvard Life Lab (2017).

Accure secured seed funding from premier angel investors (2017).